Long COVID19 prevalence among in Long COVID19 prevalence among a sample of infected people in Erbil City Long COVID19 prevalence among infected people

Main Article Content

Nihad Khalawe

Keywords

anticonvulsant hypersensitivity syndrome

Abstract

Long-term effects of the disease were founded and described as post-COVID-19 syndrome post-COVID syndrome are the symptoms that develop and last for four weeks or even months and cannot be explained by an alternative diagnosis, symptoms may remain for more than three months, The cause of persistent symptoms is unclear, Objectives: This study aimed to Estimate the prevalence of residual symptoms among a sample of people infected with COVID-19 who survive and recover in Erbil city, and to find out the relation between the severity of the disease and post COVID-19 syndrome. And to know the incidence of post-COVID-19 syndrome in chronic disease patients.Patients and Methods:This cross-sectional study was conducted in 6 primary health care centers in 6 municipalities in Erbil city, Kurdistan region, Iraq. Convenience sample of randomly selected 300 patients was involved in the study depending on inclusion criteria. Over a period of 1year starting from the 1st of March 2021 till the end of February 2022.Results: The prevalence of post-COVID syndrome among the 300 cases was 54,67%, from these cases 11.7% with one symptom, 26% with two symptoms and 17% with three or more symptoms. there was significant statistical association between persistent symptoms and severity of COVID-19, Also there was significant statistical association between persistent symptoms and chronic disease, most (67.9%) respondents with post COVID-19 syndromes suffered from chronic disease, and p-value was 0.001. And there was significant statistical association between persistent symptoms and disease duration, most (73%) of cases with post COVID-19 syndrome got the disease from 7-14 days while 54.5% of them struggled with COVID-19 more than 14 days.

Abstract 388 | PDF Downloads 510 XML Downloads 104 HTML Downloads 103

References

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica: Atenei Parmensis. 2020;91(1):157.
2. McCorkell, L., Assaf, G.S., Davis, H.E., Wei, H. and Akrami, A., Patient-Led Research Collaborative: embedding patients in the Long COVID narrative. Pain reports, 2021;6(1).
3. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. Jama. 2020 Aug 11;324(6):603-5.
4. CDC (2021). COVID-19 and Your Health. [online] Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.
5. Greenhalgh T, Knight M, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370.
6. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, Greenhalgh T. Persistent symptoms after Covid-19: a qualitative study of 114 long Covid patients and draft quality criteria for services. medRxiv. 2020 Jan 1.
7. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. Jama. 2020 Aug 11;324(6):603-5.
8. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. StatPearls. Treasure Island (FL): StatPearls Publishing. 2020.
9. Amin MT, Hasan M, Bhuiya N. Prevalence of Covid-19 Associated Symptoms, Their Onset and Duration, and Variations Among Different Groups of Patients in Bangladesh. Frontiers in public health. 2021;9:738352.
10. Khalaf M, Bazeed SE, Abdel-Gawad M, Abdelmalek M, Abu-Elfatth A, Abdelhamed W, et al. Prevalence and predictors of persistent symptoms after clearance of SARS-CoV-2 infection: a report from Egypt. 2020.
11. Garner P. Covid-19 at 14 weeks—phantom speed cameras, unknown limits, and harsh penalties. The BMJ Opinion. 2020.
12. Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Scientific reports. 2021;11(1):1-11.
13. Balachandar V, Mahalaxmi I, Subramaniam M, Kaavya J, Senthil Kumar N, Laldinmawii G, et al. Follow-up studies in COVID-19 recovered patients -is it mandatory? The Science of the total environment. 2020;729.
14. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: a cross‐sectional evaluation. Journal of medical virology. 2021;93(2):1013-22.
15. Gebhard CE, Suetsch C, Bengs S, Deforth M, Buehler KP, Hamouda NN, et al. Sex-and gender-specific risk factors of post-COVID-19 syndrome: a population-based cohort study in Switzerland. medRxiv. 2021.
16. Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
17. Nachimuthu S, Vijayalakshmi R, Sudha M, Viswanathan V. Coping with diabetes during the COVID - 19 lockdown in India: Results of an online pilot survey. Diabetes & metabolic syndrome. 2020;14(4):579-82.
18. Saqib MAN, Siddiqui S, Qasim M, Jamil MA, Rafique I, Awan UA, et al. Effect of COVID-19 lockdown on patients with chronic diseases. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(6):1621-3.
19. Alsaied T, Aboulhosn JA, Cotts TB, Daniels CJ, Etheridge SP, Feltes TF, et al. Coronavirus disease 2019 (COVID‐19) pandemic implications in pediatric and adult congenital heart disease. Journal of the American Heart Association. 2020;9(12):e017224.
20. Raveendran A, Misra A. Post COVID-19 syndrome (“Long COVID”) and diabetes: challenges in diagnosis and management. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(5):102235.
21. Amin MT, Hasan M, Bhuiya NMMA. Prevalence of Covid-19 Associated Symptoms, Their Onset and Duration, and Variations Among Different Groups of Patients in Bangladesh. Frontiers in public health. 2021;9.
22. Hopkinson NS, Rossi N, El-Sayed Moustafa J, Laverty AA, Quint JK, Freidin M, et al. Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. Thorax. 2021;76(7):714-22.
23. Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clinics and Practice. 2020;10(2):1271.
24. Edeas M, Saleh J, Peyssonnaux C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? International Journal of Infectious Diseases. 2020;97:303-5.